On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...
A Nasdaq delisting notice last week indicated that the deal was tentatively scheduled to close on Monday after Alimera (ALIM) holders vote to approve the deal at a meeting on Sept. 4.
Alimera Sciences has filed a lawsuit in the Delaware Court of Chancery to compel ANI Pharmaceuticals to fulfill its contractual obligation to close the transaction contemplated by the companies ...
Results that may be inaccessible to you are currently showing.